Physician profile
Krishna Patel
NPI 1588231120
$1,743.71
in general payments reported to CMS, 2019-2025
23 companies · $649 in 2025
The $649 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $44.58 · 2023: $193 · 2024: $857 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $228.92 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Gilead Sciences, INC. | $171.46 | 2024-2025 | |
| Abbvie INC. | $159.24 | 2024-2025 | |
| Pfizer INC. | $148.48 | 2023-2024 | |
| Boston Scientific Corporation | $128.28 | 2022-2025 | Watchman Flx, Versacross Access Solution, Watchman Access System |
| Abbott Laboratories | $120.41 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $112.68 | 2024-2025 | Farxiga, Airsupra |
| Viiv Healthcare Company | $110.03 | 2024-2025 | Apretude |
| Lilly USA, LLC | $108.78 | 2023-2024 | Omvoh, Zepbound |
| Corium, LLC | $67.41 | 2023 | Azstarys |
| Exact Sciences Corporation | $47.33 | 2024 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $46.67 | 2024 | |
| Tris Pharma INC | $44.89 | 2024-2025 | Dyanavel Xr |
| Bayer Healthcare Pharmaceuticals INC. | $39.48 | 2024-2025 | |
| Celgene Corporation | $35.17 | 2024 | Zeposia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $31.13 | 2023 | Inspire |
| Edwards Lifesciences Corporation | $27.99 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $21.94 | 2025 | Otezla, Repatha |
| Mayne Pharma Commercial LLC | $21.78 | 2024 | |
| Noven Therapeutics, LLC | $21.60 | 2025 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $20.23 | 2024 | Trintellix |
| Scpharmaceuticals INC. | $15.28 | 2025 | |
| Supernus Pharmaceuticals, INC. | $14.53 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.